Table 2 Ongoing clinical trials with identified siRNAs in cancer (ClinicalTrials.gov.)
From: Noncoding RNAs in cancer therapy resistance and targeted drug development
SiRNA targets | NCT number | Title | Cancer | Phases |
|---|---|---|---|---|
VEGF | NCT00306904 | Safety and efficacy study of small interfering RNA molecule (Cand5) to treat diabetic macular edema | Diabetic macular edema | Phase 2 |
MYC | NCT02314052 | Phase Ib/2, multicenter, dose escalation study of DCR-MYC in patients with hepatocellular carcinoma | Hepatocellular carcinoma | Phase 1 Phase 2 |
PD-L1 PD-L2 | NCT02528682 | MiHA-loaded PD-L-silenced DC vaccination after allogeneic SCT | Hematological malignancies | Phase 1 Phase 2 |
Mutated KRAS | NCT01676259 | A phase 2 study of siG12D LODER in combination with chemotherapy in patients with locally advanced pancreatic cancer | Pancreatic ductal adenocarcinoma pancreatic cancer | Phase 2 |
PKN3 | NCT01808638 | Atu027 plus gemcitabine in advanced or metastatic pancreatic cancer (Atu027-I-02) | Carcinoma, pancreatic ductal | Phase 1 Phase 2 |
EphA2 | NCT01591356 | EphA2 gene targeting using neutral liposomal small interfering RNA delivery | Advanced cancers | Phase 1 |
LMP2 LMP7 MECL1 | NCT00672542 | Immunotherapy of melanoma with tumor antigen RNA and small inhibitory RNA transfected autologous dendritic cells | Metastatic melanoma Absence of CNS metastases | Phase 1 |
APN401 | NCT02166255 | APN401 in treating patients with melanoma, kidney cancer, pancreatic cancer, or other solid tumors that are metastatic or cannot be removed by surgery | Recurrent melanoma Recurrent pancreatic cancer Recurrent renal cell cancer Stage III/IV pancreatic cancer Stage III renal cell cancer Stage IIIA/B/C/IV Melanoma Stage IV renal cell cancer | Phase 1 |
PLK1 | NCT01437007 | TKM 080301 for primary or secondary liver cancer | Colorectal cancer with hepatic metastases Pancreas cancer with hepatic metastases Gastric cancer with hepatic metastases Breast cancer with hepatic metastases Ovarian cancer with hepatic metastases | Phase 1 |
M2 | NCT00689065 | Safety study of CALAA-01 to treat solid tumor cancers | Solid tumor | Phase 1 |
AHR | NCT01075360 | The role of aromatic hydrocarbon receptor in the tumorigenesis of neuroblastoma and its relationship with MYCN expression | Neuroblastoma | Recruiting |
B4GALNT3 | NCT01058798 | The role of glycosyltransferases in the oncogenesis of neuroblastoma | Neuroblastoma | Recruiting |
BCL-B | NCT01270009 | Role of BCL-B in multiple myeloma | Multiple myeloma | Not yet recruiting |